Aclarion, Inc. (ACONW) stock
ACONWNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as ACON
$0.02+0.00 (0.00%)
Close on Oct 30, 2026Market cap $5.62MP/E –Yield –
Aclarion revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Aclarion's revenue for the twelve months ending Jun 30, 2026 was $83.77K, up 33.1% year over year. For fiscal 2025 it was $75.73K, up 65.6% from the year before. The highest annual figure on record is $75.73K in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.73K | +65.6% |
| FY2024 | Dec 31, 2024 | $45.72K | -39.4% |
| FY2023 | Dec 31, 2023 | $75.40K | +24.8% |
| FY2022 | Dec 31, 2022 | $60.44K | +0.3% |
| FY2021 | Dec 31, 2021 | $60.29K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $25.21K | +30.5% |
| Q1 FY2026 | Mar 31, 2026 | $21.14K | +11.3% |
| Q4 FY2025 | Dec 31, 2025 | $18.48K | +80.6% |
| Q3 FY2025 | Sep 30, 2025 | $18.94K | +31.5% |
| Q2 FY2025 | Jun 30, 2025 | $19.32K | +76.1% |
| Q1 FY2025 | Mar 31, 2025 | $18.99K | +87.8% |
| Q4 FY2024 | Dec 31, 2024 | $10.23K | -25.8% |
| Q3 FY2024 | Sep 30, 2024 | $14.41K | -24.4% |
| Q2 FY2024 | Jun 30, 2024 | $10.97K | -35.7% |
| Q1 FY2024 | Mar 31, 2024 | $10.11K | -60.3% |
| Q4 FY2023 | Dec 31, 2023 | $13.80K | -38.7% |
| Q3 FY2023 | Sep 30, 2023 | $19.07K | +4.6% |
| Q2 FY2023 | Jun 30, 2023 | $17.07K | +42.5% |
| Q1 FY2023 | Mar 31, 2023 | $25.47K | +134.4% |
| Q4 FY2022 | Dec 31, 2022 | $22.52K | -12.1% |
| Q3 FY2022 | Sep 30, 2022 | $18.22K | +54.0% |
| Q4 FY2021 | Dec 31, 2021 | $11.98K | – |
| Q3 FY2021 | Sep 30, 2021 | $10.87K | – |
| Q2 FY2021 | Jun 30, 2021 | $25.62K | – |
| Q1 FY2021 | Mar 31, 2021 | $11.83K | – |